HomeTrialNCT06408935
🔬NCT06408935Phase 3RECRUITING

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

Study Summary

The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.

Conditions
Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment112 participants
Primary Completion
Lead SponsorJanssen-Cilag Ltd.
Data Retrieved2026-04-11 02:55:31.550424+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.